Trending Stock News

As Immunomedics (IMMU) Stock Price Rose, Holder Rhenman & Partners Asset Management Ab Decreased Its Position by $910,000; As Red Lion Hotels (RLH) Stock Value Rose, Shareholder Raffles Associates LP Lowered Stake

Red Lion Hotels Corporation (NYSE:RLH) Logo

Raffles Associates Lp decreased its stake in Red Lion Hotels Corp (RLH) by 68.46% based on its latest 2018Q1 regulatory filing with the SEC. Raffles Associates Lp sold 217,855 shares as the company’s stock rose 0.99% while stock markets declined. The hedge fund held 100,385 shares of the hotels and resorts company at the end of 2018Q1, valued at $979,000, down from 318,240 at the end of the previous reported quarter. Raffles Associates Lp who had been investing in Red Lion Hotels Corp for a number of months, seems to be less bullish one the $286.90M market cap company. The stock decreased 0.42% or $0.05 during the last trading session, reaching $11.85. About 12,587 shares traded. Red Lion Hotels Corporation (NYSE:RLH) has risen 58.14% since June 14, 2017 and is uptrending. It has outperformed by 45.57% the S&P500. Some Historical RLH News: 06/03/2018 RLH Corporation Closes Sale of Three Additional Hotels for $29.9 Million; 22/05/2018 – RLH Corp Announces Long Term Consulting Agreement With Key Executives; 23/04/2018 – RED LION HOTELS CORP – COMMITMENT AUTOMATICALLY TERMINATES ON MAY 31, 2018 IF COMPANY HAS NOT CLOSED LOAN PRIOR TO THAT DATE; 07/05/2018 – RED LION HOTELS CORP – CONSISTENT WITH ORIGINAL AGREEMENT, AGGREGATE PURCHASE PRICE REMAINS $27 MLN; 22/05/2018 – Red Lion Hotels: Bloss and Moyle Will End Employment With Co Effective May 31; 22/05/2018 – RED LION HOTELS CORP – ENTERED INTO CONSULTING AGREEMENTS WITH ROGER BLOSS, BERNARD (BERNIE) MOYLE WHICH WILL CONTINUE THROUGH 2020; 22/05/2018 – RED LION HOTELS CORP – BLOSS & MOYLE AGREED TO END THEIR EMPLOYMENT WITH CO EFFECTIVE MAY 31, 2018, AND START THEIR CONSULTING WORK ON JUNE 1, 2018; 24/05/2018 – RLH Corporation Increases Group Commission to 11%; 10/04/2018 – RLH Corporation Appoints Kristin Thielking to Lead Human Re; 04/04/2018 – RLH IN PACT TO BUY KNIGHTS INN BRAND FROM WYNDHAM HOTEL GROUP

Rhenman & Partners Asset Management Ab decreased its stake in Immunomedics Inc (IMMU) by 13.53% based on its latest 2018Q1 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 65,000 shares as the company’s stock rose 31.75% while stock markets declined. The institutional investor held 415,330 shares of the health care company at the end of 2018Q1, valued at $6.07M, down from 480,330 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Immunomedics Inc for a number of months, seems to be less bullish one the $4.06B market cap company. The stock decreased 0.37% or $0.09 during the last trading session, reaching $24.24. About 807,721 shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 204.95% since June 14, 2017 and is uptrending. It has outperformed by 192.38% the S&P500. Some Historical IMMU News: 16/05/2018 – lmmunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer; 21/05/2018 – Immunomedics Submits Biologics License Application for Sacituzumab Govitecan to the U.S. FDA; 09/04/2018 – Top AstraZeneca I/O vet Robert Iannone jumps to Immunomedics as R&D chief as BLA looms $IMMU; 09/04/2018 – IMMUNOMEDICS NAMES IANNONE HEAD OF R&D, CHIEF MEDICAL OFFICER; 16/05/2018 – Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer; 21/05/2018 – lmmunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration; 21/05/2018 – IMMUNOMEDICS INC – FILING IS BASED ON PHASE 1/2 DATA OF SACITUZUMAB GOVITECAN IN MTNBC; 09/05/2018 – IMMUNOMEDICS 3Q LOSS/SHR 21C, EST. LOSS/SHR 15C; 10/04/2018 – ICYMI: Top AstraZeneca I/O vet Robert Iannone jumps to Immunomedics as R&D chief as BLA looms $IMMU $AZN; 21/05/2018 – IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION

Since May 23, 2018, it had 0 insider buys, and 7 sales for $6.21 million activity. Another trade for 240,000 shares valued at $2.42 million was made by Columbia Pacific Opportunity Fund – L.P. on Wednesday, May 23. The insider Mount Gregory T sold 10,000 shares worth $112,700.

More important recent Red Lion Hotels Corporation (NYSE:RLH) news were published by: Globenewswire.com which released: “RLH Corporation Promotes Amanda Marcello to Senior Vice President of Brand Strategy” on June 13, 2018, also Globenewswire.com published article titled: “RLH Corporation Increases Group Commission to 11%”, Globenewswire.com published: “RLH Corporation Announces Long Term Consulting Agreement With Key Executives” on May 22, 2018. More interesting news about Red Lion Hotels Corporation (NYSE:RLH) was released by: Globenewswire.com and their article: “RLH Corporation Appoints Gary Sims Chief Operating Officer” with publication date: June 06, 2018.

Among 2 analysts covering Red Lion Hotels (NYSE:RLH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Red Lion Hotels had 9 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital with “Buy” on Thursday, March 29. FBR Capital maintained it with “Buy” rating and $14.5000 target in Wednesday, April 18 report. The stock of Red Lion Hotels Corporation (NYSE:RLH) has “Buy” rating given on Monday, October 30 by B. Riley & Co. The firm has “Buy” rating by FBR Capital given on Friday, January 26. B. Riley & Co maintained Red Lion Hotels Corporation (NYSE:RLH) on Tuesday, August 1 with “Buy” rating. The firm has “Buy” rating given on Thursday, August 6 by Zacks. The stock of Red Lion Hotels Corporation (NYSE:RLH) earned “Buy” rating by FBR Capital on Wednesday, May 9. The company was maintained on Wednesday, March 7 by FBR Capital. FBR Capital maintained Red Lion Hotels Corporation (NYSE:RLH) on Thursday, November 30 with “Buy” rating.

Analysts await Red Lion Hotels Corporation (NYSE:RLH) to report earnings on August, 2. They expect $0.07 EPS, up 600.00% or $0.06 from last year’s $0.01 per share. RLH’s profit will be $1.69 million for 42.32 P/E if the $0.07 EPS becomes a reality. After $-0.26 actual EPS reported by Red Lion Hotels Corporation for the previous quarter, Wall Street now forecasts -126.92% EPS growth.

Investors sentiment decreased to 0.97 in Q1 2018. Its down 1.08, from 2.05 in 2017Q4. It fall, as 9 investors sold RLH shares while 21 reduced holdings. 12 funds opened positions while 17 raised stakes. 15.27 million shares or 3.27% less from 15.79 million shares in 2017Q4 were reported. Washington Bancshares reported 68,109 shares stake. Grp Inc Inc Inc holds 0% or 10,595 shares. Sei Investments accumulated 800 shares. Ameritas Inv Partners has 1,106 shares. Ny State Common Retirement Fund has 14,600 shares for 0% of their portfolio. Raffles Associate LP stated it has 100,385 shares. The Massachusetts-based Rutabaga Capital Ltd Limited Liability Company Ma has invested 1.15% in Red Lion Hotels Corporation (NYSE:RLH). Tiaa Cref Investment Ltd Company has 45,011 shares for 0% of their portfolio. Bridgeway holds 0.02% of its portfolio in Red Lion Hotels Corporation (NYSE:RLH) for 202,100 shares. Bancorporation Of Ny Mellon Corp holds 63,541 shares. Punch & Inv Mgmt Incorporated has invested 0.6% of its portfolio in Red Lion Hotels Corporation (NYSE:RLH). Royal Bancorp Of Canada owns 51,910 shares or 0% of their US portfolio. 8,048 are held by Acadian Asset Mgmt Limited Liability Corp. Millennium Mgmt Limited Co invested in 139,686 shares. Vanguard Gru has 753,288 shares for 0% of their portfolio.

Raffles Associates Lp, which manages about $93.23 million US Long portfolio, upped its stake in Fortuna Silver Mines Inc (NYSE:FSM) by 140,000 shares to 190,000 shares, valued at $990,000 in 2018Q1, according to the filing.

Rhenman & Partners Asset Management Ab, which manages about $811.26 million US Long portfolio, upped its stake in Humana Inc (NYSE:HUM) by 10,000 shares to 68,000 shares, valued at $18.28 million in 2018Q1, according to the filing. It also increased its holding in Bristol Myers Squibb Co (NYSE:BMY) by 220,198 shares in the quarter, for a total of 350,000 shares, and has risen its stake in Abbvie Inc (NYSE:ABBV).

More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Globenewswire.com which released: “Immunomedics to Present at Jefferies 2018 Global Healthcare Conference” on May 30, 2018, also Globenewswire.com with their article: “Immunomedics Announces Proposed Public Offering of Common Stock” published on June 11, 2018, Seekingalpha.com published: “Immunomedics: Short Term Risk, Long Term Opportunity” on June 13, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Benzinga.com and their article: “7 Stocks Moving In Monday’s After-Hours Session” published on June 12, 2018 as well as Nasdaq.com‘s news article titled: “Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today” with publication date: June 04, 2018.

Since February 28, 2018, it had 0 insider purchases, and 1 sale for $2.05 million activity.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on August, 15. They expect $-0.14 earnings per share, up 44.00% or $0.11 from last year’s $-0.25 per share. After $-0.14 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 4 analysts covering Immunomedics (NASDAQ:IMMU), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 18 analyst reports since July 29, 2015 according to SRatingsIntel. FBR Capital initiated it with “Buy” rating and $5300 target in Wednesday, June 6 report. Cowen & Co maintained the stock with “Buy” rating in Wednesday, December 6 report. The firm has “Buy” rating by Cowen & Co given on Monday, July 24. The firm earned “Buy” rating on Friday, June 9 by Jefferies. The firm has “Buy” rating given on Wednesday, December 6 by Jefferies. Cowen & Co maintained Immunomedics, Inc. (NASDAQ:IMMU) rating on Wednesday, August 16. Cowen & Co has “Buy” rating and $15.0 target. The firm has “Buy” rating by Jefferies given on Friday, May 6. The stock has “Buy” rating by Jefferies on Monday, October 9. Jefferies downgraded the shares of IMMU in report on Wednesday, July 29 to “Hold” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Thursday, October 6.

Investors sentiment increased to 1.26 in Q1 2018. Its up 0.19, from 1.07 in 2017Q4. It improved, as 15 investors sold IMMU shares while 46 reduced holdings. 26 funds opened positions while 51 raised stakes. 117.56 million shares or 0.32% more from 117.18 million shares in 2017Q4 were reported. Td Asset Inc has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Benjamin F Edwards & Inc holds 0% or 664 shares in its portfolio. Invesco Limited holds 324,181 shares or 0% of its portfolio. Shaker Investments Lc Oh has invested 0.24% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Thompson Davis & Inc invested 0.03% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Panagora Asset Management reported 0.03% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Schwab Charles Invest Mngmt has invested 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). California State Teachers Retirement Systems has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU). Fred Alger Management stated it has 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). Jane Street Group Limited Liability Co reported 11,673 shares stake. Citigroup Incorporated reported 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Virtu Fincl Limited Liability Company, a New York-based fund reported 22,546 shares. Goldman Sachs holds 594,252 shares. Quantitative Systematic Strategies Limited Com invested in 12,296 shares. Atlantic Group Ltd Co owns 89,292 shares for 0.01% of their portfolio.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *